General discussion, page-4121

GW is a lot more than just that one drug. They are a seed to drug company. They have worked out a way harvesting a stable and consistant product. And have specialised in oil extraction techniques. They market the drug, well a couple of drugs.

They really are a one stop shop. If you were going to enter the medical cannabis sector for the first time GW, with its experience from seed to drug, and registered drug expertise would be a low risk buy.

GW is unique and all alone in its space. So I dont think comparisomes between GW and most other medical cannabis companies are justified.

IHL is walking its own path. Not too dissimiliar to a normal biotech. Which is a pretty profitable path to be on. In its favour, it is in drug design of products which will be safer, cause less dependency and treat needs that have incomplete standard of care at the moment.

I held GW for a five years and just doubled my original investment. I have held IHL for less time, free hold 1.5 million shares which are up almost 4 bags since my initial investment. I wish my GW holding performed as well as my IHL holding. And IHL have yet to get a drug into a human!